Last updated: July 17, 2026
Litigation summary and analysis: Salix Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc. (1:17-cv-00329)
Executive summary: The docket entry 1:17-cv-00329 is a U.S. patent infringement case brought by Salix Pharmaceuticals, Inc. against Teva Pharmaceuticals USA, Inc. The litigation record in the case file determines (i) which patents were asserted, (ii) whether Salix sought preliminary relief, (iii) the claim constructions and dispositive rulings, (iv) any stipulated dismissal or final judgment, and (v) whether a settlement or consent judgment delayed generic market entry.
However, no case-specific substance is provided here (no asserted patent numbers, claim categories, FDA product and Orange Book context, filings like complaint/answer/Markman order, or outcomes). Without those docket particulars, a complete and accurate litigation summary and patent-strength analysis cannot be produced.
What claims and patents were asserted in Salix v. Teva 1:17-cv-00329?
Answer (required for a valid litigation summary): Identify the asserted patents, including:
- U.S. patent numbers in the complaint
- The asserted claims (method-of-use vs formulation vs composition)
- Alleged infringement theory tied to Teva’s ANDA label and manufacturing
- Whether any patents were dismissed as withdrawn, conceded, or non-infringed at claim construction
Status: Not determinable from the information provided.
Which drug product (ANDA/NDA) does the case target?
A litigation summary depends on mapping the infringement claims to:
- Teva’s proposed product strength(s), dosage form(s), and route
- Whether it is a reformulation, new indication, or generics-to-brand “skinny label” scenario
- The Orange Book listing(s) that triggered the Paragraph IV filing
Status: Not determinable from the information provided.
What litigation procedural posture existed?
A “litigation summary and analysis” typically requires:
- Complaint filing date and initial asserted scope
- Answer and defenses (invalidity grounds, non-infringement, inequitable conduct)
- Claim construction (Markman) schedule and rulings
- Motions for summary judgment
- Trial outcome or stipulated termination
- Any appellate activity
Status: Not determinable from the information provided.
What did the court rule on claim construction, invalidity, and infringement?
Answer (required for analysis): Litigation analysis must include:
- Claim construction outcomes (terms, limits, and functional language)
- How those constructions impacted infringement findings
- Invalidity determinations (novelty, obviousness, §112 enablement/definiteness, written description)
- Any stipulations or partial summary judgments
Status: Not determinable from the information provided.
Were any patents held unenforceable or invalid?
This determines:
- Whether Salix’s estate was weakened or preserved
- Whether Teva’s entry risk falls to other remaining patents/exclusivities
- Whether a later re-adjudication exists
Status: Not determinable from the information provided.
Did the court grant or deny any preliminary injunction?
For infringement disputes involving brand-protective strategies:
- preliminary injunction decisions can signal claim strength
- settlement leverage often correlates to early injunction outcomes
Status: Not determinable from the information provided.
When does Teva’s generic entry risk window open or close?
Answer (required for exclusivity/generic timing): Determine:
- The earliest date Teva could launch absent a stay
- Whether the court entered a section 271(e)(4) stay duration
- The status of other listed Orange Book patents
- Whether the litigation ended in a dismissal, final judgment, or settlement with launch/payment terms
Status: Not determinable from the information provided.
What patents likely drive the stay (Orange Book mechanics)?
A practical timing analysis requires:
- Which listed Salix patents were asserted (and whether any were found not infringed)
- Whether any patents expire during litigation (and how that affects remedies)
Status: Not determinable from the information provided.
What settlement terms affected competition in Salix v. Teva 1:17-cv-00329?
Answer (required for commercial analysis): A meaningful litigation summary includes:
- whether the case settled
- whether there was a stipulated dismissal with retained jurisdiction
- any agreement-driven launch date
- any consent judgment specifying permissible manufacturing, labeling, or design-around constraints
Status: Not determinable from the information provided.
Did the case end in dismissal, consent judgment, or final judgment?
This affects:
- whether Teva retains the right to launch immediately
- whether the brand’s remaining patents continue to block entry
- whether future generics face the same defenses
Status: Not determinable from the information provided.
How strong is the Salix patent estate implied by the outcome?
Answer (required for “patent strength”): Patent estate strength depends on:
- which asserted patents survived dispositive motions
- jury or court findings if tried
- whether key invalidity theories failed
- whether the court adopted broad or narrow claim constructions favorable to infringement
Status: Not determinable from the information provided.
Did the court’s rulings suggest likely survival for related continuation patents?
Brands often assert:
- continuations or continuation-in-part family members
- different claim categories (composition, formulation, method-of-use)
- different legal theories (statutory obviousness vs §112 issues)
Status: Not determinable from the information provided.
Does this case create biosimilar or follow-on generic risk for other products?
Answer (biosimilar comparison required): A biosimilar risk analysis applies only if the asserted product is biologics. This matter is identified only by party names and a civil action number; the biologics status cannot be inferred without the docket’s product information.
Status: Not determinable from the information provided.
Key Takeaways
- A complete litigation summary requires the asserted patent numbers, procedural orders, and case disposition tied to 1:17-cv-00329.
- No case-specific litigation substance (patent list, claim construction outcomes, infringement/invalidity rulings, or final disposition) is available in the provided input, so an accurate summary and enforceability analysis cannot be generated.
FAQs
- Which patents did Salix assert against Teva in 1:17-cv-00329?
- What was the court’s claim construction in Salix v. Teva (1:17-cv-00329)?
- Did the court grant summary judgment or hold any asserted claims invalid or not infringed?
- Was there a settlement or consent judgment that delayed Teva’s ANDA launch?
- What Orange Book patents remained after the case outcome and affected generic entry?
References
- No sources were provided in the prompt, and no case document details are included to support citation.
